Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lexeo Therapeutics is a clinical-stage gene therapy company developing treatments for cardiovascular and central nervous system diseases using adeno-associated virus (AAV) delivery platforms. The company's lead programs include LX1001 for APOE4-associated Alzheimer's disease and LX2006 for Friedreich's ataxia, both in early clinical development. With zero revenue, $100M annual cash burn, and 7.4x current ratio, Lexeo has approximately 18-24 months of runway based on current burn rate.
Lexeo operates as a clinical-stage biotech with no current revenue, funded entirely by equity raises and potential non-dilutive financing. The business model depends on successfully advancing AAV-based gene therapies through Phase 1/2 trials, demonstrating clinical proof-of-concept, then either partnering with large pharma for commercialization (upfront payments, milestones, royalties) or pursuing independent FDA approval for rare disease indications with orphan drug pricing power ($200K-$500K annual treatment costs). Gene therapy economics are characterized by one-time curative treatments with high upfront costs but potential lifetime value capture.
Clinical trial data readouts for LX1001 (Alzheimer's) and LX2006 (Friedreich's ataxia) - safety, biomarker, and efficacy signals
FDA regulatory interactions - IND clearances, Fast Track/Orphan Drug designations, clinical hold risks
Partnership announcements with large pharma for co-development or licensing deals (typical $50-200M upfront)
Cash runway updates and equity financing announcements - dilution concerns with $100M annual burn
Competitive gene therapy data from Sangamo, Passage Bio, or other AAV platform companies
AAV immunogenicity and safety concerns - industry-wide scrutiny following adverse events in gene therapy trials could trigger FDA clinical holds or require costly protocol modifications
Manufacturing scalability challenges for clinical-grade AAV vectors with limited CDMO capacity industry-wide, potentially delaying trials
Regulatory pathway uncertainty for CNS gene therapies with limited precedent for approval standards and biomarker acceptance
Crowded Alzheimer's landscape with 150+ programs including established antibody therapies (Leqembi, Kisunla) and competing gene therapy approaches from better-capitalized competitors
Friedreich's ataxia competition from Reata Pharmaceuticals (Skyclarys approved), PTC Therapeutics, and other gene therapy developers with more advanced programs
Platform risk if competing AAV capsid technologies or alternative delivery modalities (lipid nanoparticles, exosomes) demonstrate superior CNS penetration or safety profiles
Significant dilution risk with 18-24 month cash runway requiring $75-150M equity raise by Q4 2026, likely at depressed valuation given -31% three-month performance
High cash burn rate of $100M annually with no near-term revenue, creating dependency on capital markets access during uncertain biotech funding environment
Minimal debt cushion (0.07 D/E) provides no alternative financing flexibility if equity markets become inaccessible
low - Pre-revenue biotechs are largely insulated from GDP fluctuations as they have no commercial operations. However, severe recessions can impact ability to raise capital and reduce M&A/partnership activity from large pharma. Clinical trial execution is relatively GDP-independent, though patient recruitment can slow marginally during economic stress.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (8-12 years until potential commercialization). Clinical-stage biotechs trade at high multiples of future revenue, making them particularly sensitive to risk-free rate changes. Higher rates also increase cost of capital for future equity raises and reduce appetite for speculative growth assets. With minimal debt (0.07 D/E), direct financing cost impact is negligible.
Minimal - Company has negligible debt and funds operations through equity. Credit market conditions indirectly affect ability to secure non-dilutive financing (venture debt, royalty financing) and impact large pharma partners' willingness to deploy capital for licensing deals during credit stress.
growth - Attracts high-risk, high-reward biotech specialists and venture-style investors betting on binary clinical outcomes. Typical holders include dedicated healthcare funds, crossover investors, and retail speculators. Not suitable for value or income investors given negative earnings, zero revenue, and no dividend. Stock trades on clinical catalyst anticipation with 6-12 month holding periods around data readouts.
high - Clinical-stage biotechs exhibit extreme volatility with 50-80% single-day moves on trial data. Beta likely exceeds 2.0x relative to broader market. Recent performance shows characteristic volatility: -31% three-month, +32% six-month, +41% one-year. Small $500M market cap amplifies price swings on modest volume. Implied volatility typically 80-120% ahead of clinical catalysts.
